Clinical Trial Update: Safety Study of CC312 in Autoimmune Disease Patients [EARLY_Phase 1]

View source ↗

Summary

Early-phase safety study of CC312 in multiple autoimmune diseases is currently recruiting, sponsored by CytoCares Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Idiopathic Inflammatory Myopathy
• Immune Thrombocytopenia
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CC312 (CC312)

Snippet

Sponsor: CytoCares Inc | Conditions: Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM) | EARLY_Phase 1 | Status: RECRUITING